Keeping Track: Early Thanks Given By ImmunoGen, Provention Bio; More PD-1/L1 Combo Approvals
Executive Summary
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
You may also be interested in...
ADCs Coming Of Age: Deals, Targets And Catalysts
The antibody-drug conjugate field is beginning to reach its full potential and big pharma’s attention has been caught.
ImmunoGen’s First ADC For Ovarian Cancer To Exceed Sales Expectations
ImmunoGen’s Elahere, the only antibody-drug conjugate approved for platinum-resistant ovarian cancer in the US, will produce better than anticipated sales for the first quarter of 2023, CEO Mark Enyedy hinted in a recent interview.
Provention Plans Two-Phase Launch Of Tzield, Pricing Drug Higher Than Expected
At nearly $194,000, the wholesale acquisition cost for Tzield came in above analysts’ $100,000-$115,000 estimates, but payer pushback is not expected as the drug faces no competition.